[INM] QoQ Quarter Result on 30-Jun-2007 [#Q4]

Stock

[INM] InMed Pharmaceuticals Inc.

Announcement Date

30-Jun-2007

Financial Year

2007

Quarter

30-Jun-2007 [#Q4]

Profit Trend

QoQ- -272.37%

YoY- -308.17%

Quarter Report

INM's Result

INM's Financial Summary

View:

Show?

YoY %

Horiz. %

	31/03/08	31/12/07	30/09/07	30/06/07	31/03/07	31/12/06	30/09/06	CAGR
Quarter Result
Revenue	430	506	410	541	437	337	433	-0.46%
YoY %	-15.02%	23.41%	-24.21%	23.80%	29.67%	-22.17%	-	-
Horiz. %	99.31%	116.86%	94.69%	124.94%	100.92%	77.83%	100.00%	-
PBT	-185	-427	-234	7,902	-228	-516	-250	-18.17%
YoY %	56.67%	-82.48%	-102.96%	3,565.79%	55.81%	-106.40%	-	-
Horiz. %	74.00%	170.80%	93.60%	-3,160.80%	91.20%	206.40%	100.00%	-
Tax	3	8	-31	8,751	20	0	49	-84.43%
YoY %	-62.50%	125.81%	-100.35%	43,655.00%	0.00%	0.00%	-	-
Horiz. %	6.12%	16.33%	-63.27%	17,859.18%	40.82%	0.00%	100.00%	-
NP	-188	-424	-270	-849	-228	-581	-311	-28.48%
YoY %	55.66%	-57.04%	68.20%	-272.37%	60.76%	-86.82%	-	-
Horiz. %	60.45%	136.33%	86.82%	272.99%	73.31%	186.82%	100.00%	-
Tax Rate	-	-	-	-110.74%	-	-	-	-
YoY %	-	-	-	0.00%	-	-	-	-
Horiz. %	-	-	-	100.00%	-	-	-	-
Total Cost	618	930	680	1,390	665	918	744	-11.62%
YoY %	-33.55%	36.76%	-51.08%	109.02%	-27.56%	23.39%	-	-
Horiz. %	83.06%	125.00%	91.40%	186.83%	89.38%	123.39%	100.00%	-

	31/03/08	31/12/07	30/09/07	30/06/07	31/03/07	31/12/06	30/09/06	CAGR
Ratio Analysis
NP Margin	-75.55	-83.86	-248.35	-156.93	-52.27	-172.35	-71.96	3.29%
YoY %	9.91%	66.23%	-58.26%	-200.23%	69.67%	-139.51%	-	-
Horiz. %	104.99%	116.54%	345.12%	218.08%	72.64%	239.51%	100.00%	-

	31/03/08	31/12/07	30/09/07	30/06/07	31/03/07	31/12/06	30/09/06	CAGR
Per Share
EPS	-52.55	-132.46	-89.57	-319.84	-82.75	-235.93	-128.73	-44.94%
YoY %	60.33%	-47.88%	72.00%	-286.51%	64.93%	-83.28%	-	-
Horiz. %	40.82%	102.90%	69.58%	248.46%	64.28%	183.28%	100.00%	-
EPS Diluted	-52.55	-129.74	-86.78	-314.62	-82.75	-235.93	-128.73	-44.94%
YoY %	59.50%	-49.50%	72.42%	-280.21%	64.93%	-83.28%	-	-
Horiz. %	40.82%	100.78%	67.41%	244.40%	64.28%	183.28%	100.00%	-

PBT = Profit before Tax, NP = Net Profit, NP Margin = Net Profit Margin, EPS = Earning Per Share, EPS Diluted = Earning Per Share Diluted.

NP Margin, QoQ ⃤ & YoY ⃤ figures in Percentage; EPS & EPS Diluted figures in Cent.

All figures in '000 unless specified.

Latest Videos

MQ Market Updates - 8 November 2024

MQ Trader

Apps

MQ Chat

Send individual or group chats with anyone on i3investor

MQ Trader

Earn MQ Points while trading with MQ Trader

MQ Affiliate

Earn side income from Affiliate Program

MQdemy

Online learning and teaching marketplace

Hot Stocks Today >

MSFT

Microsoft Corporation

1000

AVGO

Broadcom Inc.

865

AAPL

Apple Inc.

769

TSLA

Tesla, Inc.

673

Mastercard Incorporated

576

BABA

Alibaba Group Holding Limited

442

NVDA

NVIDIA Corporation

384

PLTR

Palantir Technologies Inc.

346

UPST

Upstart Holdings, Inc.

288

GOOGL

Alphabet Inc.

192

Daily Stocks

FOXO

0.496

+0.127

783,670,544

ELAB

0.019

+0.001

415,816,563

SLNA

0.03

-0.008

379,091,456

CYXT

0.065

0.00

369,807,727

NCL

0.334

+0.11

312,940,583

TIVC

0.406

+0.145

291,533,624

UWT

0.164

-0.002

244,137,454

AGIL

0.197

+0.114

206,404,986

LYLT

0.218

0.00

204,480,452

TSLA

321.22

+24.31

200,284,787

More active Stocks

BRK-A

695,878.32

+7,626.31

1,670

SEZL

431.48

+181.01

627,985

FICO

2,332.29

+156.19

257,320

AXON

603.18

+134.43

3,935,925

MELI

1,872.01

+97.96

1,321,184

NVR

9,306.94

+85.71

16,040

RTLA

209.90

+74.87

312.91

+51.65

197,882

WSO-B

518.97

+48.07

222

GHC

960.36

+44.79

20,136

More gainer Stocks

MELI

1,774.05

-343.25

2,940,447

MPWR

759.30

-160.51

2,985,808

MSTR

1,309.00

-138.99

2,237,917

MKL

1,395.13

-102.30

318,280

MTD

1,310.03

-101.49

247,326

LOWC

30.18

-92.412

1,236,074

NOW

643.29

-87.83

5,025,012

NVDA

762.00

-84.71

85,558,284

MEDP

357.30

-79.88

1,004,401

SEB

2,653.77

-73.98

2,605

More loser Stocks

Books Review >

Ride The Bull Short The Bear

CS Tan

4.9 / 5.0

This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....

Read More